持续推进营销改革 寿仙谷第三季度营收同比正增长

Core Viewpoint - Zhejiang Shouxiangu Pharmaceutical Co., Ltd. reported a revenue increase of 8.51% year-on-year for Q3 2025, demonstrating resilience in a challenging consumer market [1][2] Financial Performance - The company achieved a revenue of 130 million yuan in Q3 2025, with a net cash flow from operating activities of 20.94 million yuan, reflecting a 51.24% increase year-on-year [1] - Net profit attributable to shareholders decreased due to increased R&D investments [1] Business Strategy - The company is focusing on "marketing-driven enterprise" strategies, enhancing marketing channels, brand building, and digital marketing innovations [2] - Shouxiangu is expanding its market presence through a dual-channel approach, combining specialty store systems with traditional pharmacy channels [1][2] Product Development - The company has optimized its product matrix, launching new products such as Shouxiangu Blue and Shouxiangu Red, which cater to modern consumer trends [1][2] - Shouxiangu has established a multi-category matrix for health food products, including new beverages and solid drinks, positioning this segment as a key growth area [2] R&D Investment - R&D expenses reached 42.09 million yuan in the first three quarters, marking a 32.32% increase year-on-year, supporting the development of innovative products [3] - The company has initiated 92 research projects, including 56 collaborative projects with academic institutions, enhancing its competitive edge in the market [3] Industry Outlook - The market for health food products, particularly those derived from traditional Chinese medicine, is expected to grow due to rising health awareness and the emergence of younger consumer demographics [2][3]